438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

التفاصيل البيبلوغرافية
العنوان:	438 A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
المؤلفون:	Michael Gibson, Ammar Sukari, Julie Bauman, Tanguy Seiwert, Barbara Burtness, Sara Pai, Cristina Rodriguez, Bonnie Glisson, Kenneth Pienta, Francis Worden, Lara Dunn, Douglas Adkins, Christine Chung, A Dimitrios Colevas, Lori Wirth, Nabil Saba, Laura Agensky, Matteo Levisetti, Reena Lynam, Steven Margossian, Raymond Moniz, Steve Quayle
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
بيانات النشر:	BMJ Publishing Group, 2021.
سنة النشر:	2021
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426
DOI:	10.1136/jitc-2021-SITC2021.438
URL الوصول:	https://doaj.org/article/b2ee215c0e23467289d8660a733a8f35
رقم الأكسشن:	edsdoj.b2ee215c0e23467289d8660a733a8f35
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2021-SITC2021.438